IBT
NBIX icon

International Biotechnology Trust’s Neurocrine Biosciences NBIX Stock Holding History

International Biotechnology Trust’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$3.25M Sell
28,877
-40,000
-58% -$4.21M 1.09% 26
2023
Q2 		$6.49M Buy
+68,877
New +$6.73M 1.98% 18
2022
Q4 		– Sell
-30,000
Closed -$3.19M – 68
2022
Q3 		$3.19M Buy
30,000
+6,992
+30% +$709K 1.02% 29
2022
Q2 		$236K Sell
23,008
-179,992
-89% -$16.6M 2.46% 16
2022
Q1 		$3.15M Sell
203,000
-77,000
-28% -$6.53M 0.71% 35
2021
Q4 		$23.8M Sell
280,000
-9,500
-3% -$874K 5.31% 2
2021
Q3 		$27.7M Buy
289,500
+82,500
+40% +$7.79M 6.69% 2
2021
Q2 		$20.1M Hold
207,000
– – 5.31% 6
2021
Q1 		$20.1M Buy
207,000
+183,000
+763% +$19.2M 5.32% 4
2020
Q4 		$2.3M Sell
24,000
-197,800
-89% -$19.1M 0.63% 30
2020
Q3 		$21.3M Buy
221,800
+116,000
+110% +$13.4M 6.89% 2
2020
Q2 		$13.3M Sell
105,800
-1,500
-1% -$166K 4.41% 9
2020
Q1 		$9.29M Sell
107,300
-26,000
-20% -$2.54M 4.23% 9
2019
Q4 		$14.3M Sell
133,300
-14,000
-10% -$1.47M 5.16% 5
2019
Q3 		$13.3M Sell
147,300
-9,500
-6% -$888K 6.13% 4
2019
Q2 		$13.2M Buy
156,800
+53,200
+51% +$4.37M 4.91% 3
2019
Q1 		$9.13M Sell
103,600
-22,200
-18% -$1.86M 3.37% 7
2018
Q4 		$7.05M Buy
125,800
+90,300
+254% +$8.65M 4.38% 8
2018
Q3 		$3.35M Sell
35,500
-128,000
-78% -$14.5M 1.59% 23
2018
Q2 		$16.1M Buy
163,500
+9,500
+6% +$850K 6.17% 1
2018
Q1 		$12.8M Buy
154,000
+117,000
+316% +$9.88M 4.98% 4
2017
Q4 		$2.87M Sell
37,000
-29,000
-44% -$1.98M 1.01% 31
2017
Q3 		$4.04M Buy
+66,000
New +$3.48M 1.57% 22
2017
Q2 		– Sell
-40,264
Closed -$1.74M – 64
2017
Q1 		$1.74M Hold
40,264
– – 0.67% 34
2016
Q4 		$1.56M Buy
+40,264
New +$1.82M 0.7% 29

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

International Biotechnology Trust's NBIX Position: Q3 2023 in Review

International Biotechnology Trust reduced its Neurocrine Biosciences (NBIX) stake by 58% in Q3 2023, selling an estimated $4.21M and leaving 28,877 shares worth $3.25M. The position accounts for 1.09% of the portfolio, ranked #26.

International Biotechnology Trust first reported a position in NBIX in Q4 2016 and has held it in 25 quarters since. The position peaked at $27.7M in Q3 2021. 512 funds tracked by Wall St. Rank hold NBIX as of Q3 2023.

  • International Biotechnology Trust held 28,877 shares of Neurocrine Biosciences worth $3.25M as of Q3 2023.
  • International Biotechnology Trust sold 40,000 Neurocrine Biosciences shares in Q3 2023, an estimated $4.21M.
  • Neurocrine Biosciences made up 1.09% of International Biotechnology Trust's portfolio in Q3 2023, its #26 holding.
  • International Biotechnology Trust first reported a position in Neurocrine Biosciences in Q4 2016 and has held it in 25 quarters since.
  • International Biotechnology Trust's Neurocrine Biosciences position peaked at $27.7M in Q3 2021.
  • 512 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.